StocksMedium•20 November 2026•
1 min read

FDA Grants Rare Pediatric Disease Designation to Medivir's MIV-711

By

Key Facts

1The U.S. FDA granted Rare Pediatric Disease Designation to MIV-711 for the treatment of osteogenesis imperfecta.

The U.S. FDA granted Rare Pediatric Disease Designation to MIV-711 for the treatment of osteogenesis imperfecta. Benzinga reported that the designation is intended to incentivize the development of new drugs for serious or life-threatening diseases that primarily affect children.

MIV-711 is an investigational drug developed by Medivir targeting rare genetic bone disorders. This regulatory progress follows recent U.S. economic data showing retail sales grew 6.8% year-over-year on November 17, 2026, indicating stable consumer conditions in the domestic market.

Sources